Ondine Biomedical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Ondine Biomedical şirketinin toplam hissedar öz sermayesi CA$19.0K ve toplam borcu CA$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$4.0M ve CA$4.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

CA$0

Borç

Faiz karşılama oranı	n/a
Nakit	CA$1.22m
Eşitlik	CA$19.00k
Toplam yükümlülükler	CA$4.01m
Toplam varlıklar	CA$4.03m

Son finansal sağlık güncellemeleri

Is Ondine Biomedical (LON:OBI) In A Good Position To Invest In Growth?

Sep 28

Recent updates

Is Ondine Biomedical (LON:OBI) In A Good Position To Invest In Growth?

Sep 28

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: OBI 'nin kısa vadeli varlıkları ( CA$3.2M ) kısa vadeli yükümlülüklerini ( CA$4.0M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: OBI un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: OBI borçsuzdur.

Borcun Azaltılması: OBI un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: OBI son raporlanan serbest nakit akışına göre 1 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: OBI serbest nakit akışı tahminlerine göre 1 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Ondine Biomedical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Ondine Biomedical (LON:OBI) In A Good Position To Invest In Growth?

Recent updates

Ondine Biomedical Inc. has completed a Follow-on Equity Offering in the amount of £9 million.

Ondine Biomedical Inc. has filed a Follow-on Equity Offering in the amount of £8.5 million.

Ondine Biomedical Inc. Receives Regulatory Approval to Market Steriwave Nasal Decolonization to Reduce Healthcare-Associated Infections in Patients Undergoing Surgery in the United Arab Emirates

Consensus estimates of losses per share improve by 44%

First half 2024 earnings released: CA$0.032 loss per share (vs CA$0.041 loss in 1H 2023)

Ondine Biomedical Inc. announced that it expects to receive CAD 5 million in funding

Ondine Biomedical Inc. Announces Board and Committee Changes

Consensus EPS estimates fall by 38%

Full year 2023 earnings released: CA$0.073 loss per share (vs CA$0.10 loss in FY 2022)

Ondine Biomedical Inc. to Report Fiscal Year 2023 Final Results on Jun 07, 2024

Ondine Biomedical Inc. has completed a Follow-on Equity Offering in the amount of £3.037487 million.

New minor risk - Financial data availability

HCA Healthcare UK Approves the Steriwave Light-Activated Antimicrobial Developed by Ondine Biomedical Inc

New minor risk - Share price stability

Ondine Biomedical Inc. Announces Chief Financial Officer Changes

Ondine Biomedical Inc. Announces Steriwave Study Shows 77% Drop in Antibody Use

Ondine Biomedical Inc. Starts First UK Health Economics Study

New minor risk - Shareholder dilution

Ondine Biomedical Inc. Announces Appointment of Joseph P. Errico as Chief Financial Officer

Ondine Biomedical Inc. has completed a Follow-on Equity Offering in the amount of £2.75 million.

Ondine Biomedical Inc. has filed a Follow-on Equity Offering in the amount of £1 million.

First half 2023 earnings released: CA$0.041 loss per share (vs CA$0.044 loss in 1H 2022)

New minor risk - Financial data availability

New minor risk - Financial data availability

Ondine Biomedical Inc. to Report First Half, 2023 Results on Sep 25, 2023

New minor risk - Share price stability

Ondine Biomedical Inc. Announces Updated Phase 3 Clinical Trial

Ondine Biomedical Appoints Dr. Simon Sinclair as Chief Medical Officer

Full year 2022 earnings released: CA$0.10 loss per share (vs CA$0.63 loss in FY 2021)

Ondine Biomedical Inc. to Report Q1, 2023 Results on May 10, 2023

Ondine Biomedical Inc. Announces Publishing New Photodisinfection Study

Ondine Biomedical Inc. Announces Steriwave Receives Regulatory Approval in Mexico

Ondine Biomedical Inc. Receives Funding of Nearly $735,000 from Agriculture and Agri-Food Canada

Ondine Biomedical, Inc. Presents New Efficacy Data Against MRSA

Is Ondine Biomedical (LON:OBI) In A Good Position To Invest In Growth?

First half 2022 earnings released: CA$0.044 loss per share (vs CA$0.033 loss in 1H 2021)

Ondine Biomedical Inc. Provides Research Presented on Photodisinfection

Ondine Biomedical Reports Successful Topline Data from Phase 2 Nasal Photodisinfection Trial

Ondine Biomedical Inc. Completes Patient Recruitment for US Phase II Nasal Photodisinfection Trial

Ondine Biomedical Inc. Completes Randomised Controlled Study of Ondine

Ondine Biomedical Inc., Annual General Meeting, Jun 07, 2022

Insufficient new directors

Ondine Biomedical Inc. Announces That Photodisinfection Effective Against SARS-CoV-2

Ondine Biomedical Inc. Treats First Patients in Nasal Photodisinfection US Phase 2 for the Prevention of Post-Operative Infections

Ondine Biomedical Inc. Initiates A Clinical Trial of Its Steriwave™ Photodisinfection Technology for Nasal Disinfection in Covid-19 Patients

Ondine Biomedical Inc. has completed an IPO in the amount of £103.927594 million.

Insufficient new directors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin